Страна: Єгипет
мова: англійська
Джерело: EDA (Egyptian Drug Authority)
SANOFI AVENTIS-FRANCE
50 mg
capsule
24 capsules
ALEXANDRIA
1995-08-01
20/07/2011 16:28 - VISTAlink folder 730160 - Page 1/4 S3 CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk • NSAIDs is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. GASTROINTESTINAL RISK NSAIDs cause an increased risk of serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. COMPOSITION Each capsule contains _Active ingredient:_ Ketoprofen ………..50mg _Inactive ingredient:_ Lactose & magnesium stearate. PHARMACEUTICAL FORM Capsules. PHARMACOLOGICAL ACTION Pharmacodynamics:_ _Ketoprofen is a non-steroidal, anti-inflammatory arylcarboxylic acid derivative belonging to the propionic acid group of NSAIDs. Ketoprofen has anti-inflammatory, antipyretic properties and has central and peripheral analgesic activity. However, its mode of action is not fully explained. It inhibits prostaglandin synthetase and platelet aggregation. _Pharmacokinetics:_ Absorption: Ketoprofen is rapidly and completely absorbed from the gastrointestinal tract. Maximal plasma levels are reached within 60 to 90 minutes after oral administration (45 to 60 minutes after rectal administration). When ketoprofen is administered with food, the rate of absorption is slowed, resulting in delayed and reduce peak concentration (Cmax); however, its total bioavailibility is not altered. *Sustained-released formulations: when administered with high caloric food, a slight decrease of bioavailibility (13%) has been observed. For the different slow-release formulations available in the differe Прочитайте повний документ